Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Curcumin, Resveratrol and G04CB02 in ALS
NCT04654689Phase 2Completed
- Sponsor
- Fundación Universidad Católica de Valencia San Vicente Mártir
- Start
- Jul 2021
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dutasteride, resveratrol and curcumin in amyotrophic lateral sclerosis (ALS) (2 arms), sponsored by Fundación Universidad Católica de Valencia San Vicente Mártir. Primary endpoints: Revised Amyotrophic Lateral Sclerosis Functional Rating Scale at 4 months, Electromyography at 4 months and 1 more. Started Jul 2021; status: completed.
02
Drugs
dutasterideresveratrolcurcumin
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT04654689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04654689.